Search - tctmd.com

Displaying 61 - 80 of 112

Sort: Relevancy | Date

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Shelley Wood

November 18, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Statin Discontinuation in the Elderly Linked to More CV Events

Yael L. Maxwell

August 01, 2019

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

News Daily News

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Michael O'Riordan

July 01, 2019

News Daily News

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

Yael L. Maxwell

April 18, 2019

News Conference News ACC 2019

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Yael L. Maxwell

March 22, 2019

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News TCT 2018

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

Michael O'Riordan

October 05, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Conference News EAS 2018

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

Yael L. Maxwell

May 08, 2018

News Conference News ACC 2018

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

Michael O'Riordan

March 11, 2018

News Conference News ACC 2018

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Michael O'Riordan

March 10, 2018

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

Advertisement

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Recurrent Events Common Among Young Patients With CAD

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Statin Discontinuation in the Elderly Linked to More CV Events

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

High Levels of Lp(a) Linked to Increased Ischemic Stroke Risk

Zero CAC Reliably Excludes CAD Among Stable, Symptomatic Patients, but Experts Debate Its Need

REDUCE-IT Subanalysis: Icosapent Ethyl Reduces Total and Recurrent CV Events

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Statin Preloading Benefit More Pronounced in STEMI Patients: SECURE-PCI

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients

ODYSSEY Delivers a Win for Alirocumab in ACS, With a Signal of Survival Benefit

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content